AI assistant
CHIMERIC THERAPEUTICS LIMITED — Board/Management Information 2021
Dec 12, 2021
64648_rns_2021-12-12_a37c8157-a392-4f26-b8f3-109f3fe75bd5.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [262 x 53] intentionally omitted <==
ASX Announcement
December 13, 2021
CHIMERIC ANNOUNCES KEY MANAGEMENT CHANGES FOR 2022
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announcement several planned changes to key management roles for 2022.
Dr Eliot Bourk, Chimeric’s Vice President Business and Corporate Development since March 2021, has been promoted to the role of Chief Business Officer (CBO) and Head of External Innovation. In this new expanded role, Dr Bourk will continue to lead business and corporate development for Chimeric while taking the extended responsibility for Chimeric’s early scientific strategy.
This newly created executive role, along with a new Head of Clinical Development role to be appointed in early 2022, is reflective of the Company’s rapid portfolio growth with the addition of the CORE-NK platform in December 2021 and the CDH17 CAR T in July 2021. Alongside the CLTX CAR T program, this will lead to the initiation of multiple new clinical trials throughout 2022 and 2023.
Dr Bourk holds a PhD in molecular pathology with a research focus in cancer immunology from the University of California. Dr Bourk has worked extensively at leading cell therapy companies Celgene and Kite on the early preclinical development of multiple cell therapy assets. During his time with Chimeric to date he has enabled the Company to gain exclusivity to two highly promising and innovative assets (CHM 2101, the CDH17 CAR T and CHM 0201, the CORE-NK platform).
Having completed his initial 12-month contract with the Company, Chimeric’s Chief Medical Officer Dr Syed Rizvi will be leaving the company to pursue other opportunities in the new year. Dr Rizvi has played an important role in advancing Chimeric’s early clinical efforts and the board thanks him for his important contributions at a pivotal stage. He will remain in the role until January 2022, enabling a seamless transition of the relevant responsibilities as Chimeric identifies a new executive candidate.
“Our recent portfolio growth has resulted in the need for expertise that will allow us to rapidly advance our preclinical assets alongside multiple phase 1 clinical trials in solid tumours and blood cancers,” said Chimeric’s CEO Jennifer Chow.
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 1
==> picture [262 x 53] intentionally omitted <==
“These newly created roles will provide us with both the expertise and focus we need to continue our rapid growth and development. I am thrilled to have Eliot taking on this new executive leadership role for Chimeric, having worked with him for more than five years and knowing his deep commitment to this company, I am more than confident that he will be highly successful advancing our therapies through preclinical development to accelerate our development plans.”
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHIMERIC THERAPEUTICS
Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.
To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2[nd] CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.
CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.
Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.
CONTACT
Investors
Jennifer Chow Chief Executive Officer and Managing Director Chimeric Therapeutics T: + 1 9087238387 E: [email protected] W: www.chimerictherapeutics.com
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 2
==> picture [262 x 53] intentionally omitted <==
Paul Hopper Executive Chairman T: + 61 406 671 515
Media
Matthew Wright NWR Communications P: +61 451 896 420 E: [email protected]
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 3